Terumo Corporation · TSE:4543
Terumo — Merger or Acquisition (September 2026)
12 slides from Terumo's merger presentation, Sep 30, 2026
Slide 1: Acquisition of Arsenal Medical
Acquisition of Arsenal Medical Carsten Schroeder President Terumo Neuro September 30, 2026
Slide 2: Forward-Looking Statements and Use of Document
Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performanc
Slide 3: Executive Summary
Executive Summary Transaction Entered into a definitive agreement to acquire Arsenal Medical, a privately held, venture- backed, clinical-stage biomaterials company Financial terms not disclosed Key takeaways Adds NeoCast, an investigational next-generation liquid embolic for chronic subdural hemato
Slide 4: Acquisition Overview
Acquisition Overview Arsenal Medical Arsenal Medical, a privately held, venture-backed, clinical-stage biomaterials Target Company company Transaction Acquisition of Arsenal Medical by Terumo Neuro Structure Acquisition Funded on cash on hand Funding Financial Impact To be reflected in future financ
Slide 5: Arsenal Medical Overview
Arsenal Medical Overview About Arsenal Medical Arsenal Medical’s History Founded: 2005 2005 Founded to develop innovative biomaterials for underserved medical problems Head office: Waltham, Massachusetts, USA Privately held, venture-backed, clinical-stage biomaterials 2010’s Focused significant R&D
Slide 6: cSDH: A Significant Threat to Brain Health
cSDH: A Significant Threat to Brain Health cSDH Patient Population Collection of blood between the skull and brain Primarily affects elderly patients Expected to become the most common neurosurgical condition by 20301 Causes Fragile and leaking capillaries Head trauma, including in younger patients
Slide 7: cSDH: Current Treatment Landscape and Remaining Challenges
cSDH: Current Treatment Landscape and Remaining Challenges Standard Approach Emerging Approach - Middle meningeal artery (MMA) - Surgical Drainage - embolization - Overview Overview Common approach for immediate hematoma Used either adjunctively with or instead of surgery evacuation Targets the vasc
Slide 8: cSDH: Emerging Market Opportunity
cSDH: Emerging Market Opportunity cSDH projected to outgrow stroke and aneurysm treatment in the U.S. by 2030¹ Key Growth Drivers Projected U.S. procedures of middle meningeal artery embolization (MMAE) compared with endovascular (EV) treatment of cerebral aneurysms and acute ischemic stroke (AIS)1
Slide 9: Second Gen Liquid Embolic: NeoCast
Second Gen Liquid Embolic: NeoCast Solvent-free, non-adhesive material that utilizes shear-thinning science to reach the microvasculature, purpose-built for cSDH First-in-human evidence (EMBO-02)1 96% achieved at least 50% hematoma volume resolution 75% achieved complete resolution at final follow-u
Slide 10: Strategic Rationale of the Acquisition
Strategic Rationale of the Acquisition A two-generation strategy to lead the liquid embolic category PHIL: TN’s established liquid embolic, already used in dAVF* and AVMs* A Winning Combination One portfolio across all liquid embolic procedures and physician preferences Existing PHIL relationships b
Slide 11: Future of Terumo Neuro
Future of Terumo Neuro Driving further the Neurovascular business Not just a new product — a wider future scope for Terumo Neuro Preserving and From core to adjacent indications Restoring From treatment to brain health Brain Health Aneurysm cSDH/MMAE Core Neurovascular Adjacent Indications AIS ©TERU
Slide 12: ~“TERUMO
~“TERUMO